Publication of our economic evaluation comparing two cervical screening strategies in Belgium: HPV primary versus co-testing
Piss in a pot and pop it in the post: An economic evaluation of vaginal swab and urine self-sampling for HPV primary cervical cancer screening compared with clinician-collected sampling
A cost effectiveness analysis of repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK
Examining the acceptability of offering STI screening in higher educational settings
Cost analysis of near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges
Cluster-randomised feasibility trial of a chlamydia test and treat (TnT) service in further education colleges
How to prevent cervical cancer: HPV – we are coming to get you!
Cervical screening and HPV testing: Opportunities for rapid tests
We explored the use of a rapid, on-demand human papillomavirus (HPV) test. Interviews with UK experts revealed that a co-located, on-demand HPV test following cytology could reduce the time to cervical screening results by up to a week, with a near-patient primary HPV test followed by cytology triage could radically change the testing paradigm. A follow-up tool we built in Excel was used to understand cervical screening burden and HPV testing across Europe.
The cost of pelvic inflammatory disease and potential cost-savings of chlamydia screening
We worked with clinicians from St Georges University who had published a trial estimating the incidence of pelvic inflammatory disease (PID) among women screened and unscreened for chlamydia. Patient data was analysed, and the average cost of managing PID was estimated to be £163 in community and hospital settings, and that over £60,000 could be saved in London alone from screening for chlamydia. This paper has been cited widely and results have informed policy and further modelling studies.
How can European countries improve cervical cancer prevention for women?
